Foreign Subsidiaries

In 2002, Taiho Pharma U.S.A., Inc., was established as the US subsidiary of Taiho Pharmaceutical Co., Ltd., to provide direct management of research and development programs for obtaining marketing approvals of anticancer drugs in US and European markets.
This carefully selected team of professionals works together with medical professionals and organizations in the US and Europe, while cooperating with Taiho Pharmaceutical staff in Japan, to advance the global development of new drugs that can contribute to cancer treatment.

Product Pipeline

IND Code	Dosage Form	Indications	Development Locations	Development Stage
S-1	Oral	Gastric cancer	US	Phase III
TAS-102	Oral	Colorectal cancer	Japan, US, EU	Phase III

As of June 30, 2012

Taiho Pharmaceutical of Beijing Co., Ltd. was established in China in August 2008 as a wholly owned subsidiary of Taiho Pharmaceutical. Taiho Beijing conducts clinical development to obtain approval from authorities in China on anticancer agents researched and developed by Taiho Pharmaceutical, and academic promotion activities through Chinese oncologists. In July 2009, the company put TS-1 on the market and is currently developing its business mainly in China’s coastal areas. Aiming to gain broad recognition of Taiho among the Chinese people as a specialized firm manufacturer of anticancer agents in China, the company will contribute to cancer treatment in China by providing oncologists, other medical care professionals, and patients with drugs to support them in the battle against cancer.

Taiho Pharma Singapore Pte. Ltd. was established in Singapore in August 2011 as a wholly-owned subsidiary of Taiho Pharmaceutical Co., Ltd.
Sticking with our philosophy “by local, for local”, Taiho Pharma Singapore covers a wide range of jobs such as clinical research, regulatory affairs, medical affairs and sales as a hub for Taiho’s onocology business in South East Asia in close touch with local medical oncologists and the other medical professionals in cancer care.
Taiho Pharma Singapore hopes to share our smile and happiness with local cancer patients, medical oncologists and the other medical professionals in cancer care in South East Asia by introducing our anticancer drugs and data with high quality.